396 related articles for article (PubMed ID: 21367843)
1. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.
Thangavel C; Dean JL; Ertel A; Knudsen KE; Aldaz CM; Witkiewicz AK; Clarke R; Knudsen ES
Endocr Relat Cancer; 2011 Jun; 18(3):333-45. PubMed ID: 21367843
[TBL] [Abstract][Full Text] [Related]
2. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.
Lange CA; Yee D
Endocr Relat Cancer; 2011 Aug; 18(4):C19-24. PubMed ID: 21613412
[TBL] [Abstract][Full Text] [Related]
3. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
Knudsen ES; Witkiewicz AK
Oncotarget; 2016 Oct; 7(43):69111-69123. PubMed ID: 27564114
[TBL] [Abstract][Full Text] [Related]
4. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
5. RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models.
Kumarasamy V; Nambiar R; Wang J; Rosenheck H; Witkiewicz AK; Knudsen ES
Oncogene; 2022 Jul; 41(27):3524-3538. PubMed ID: 35676324
[TBL] [Abstract][Full Text] [Related]
6. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Finn RS; Dering J; Conklin D; Kalous O; Cohen DJ; Desai AJ; Ginther C; Atefi M; Chen I; Fowst C; Los G; Slamon DJ
Breast Cancer Res; 2009; 11(5):R77. PubMed ID: 19874578
[TBL] [Abstract][Full Text] [Related]
7. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
8. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
Harada M; Morikawa M; Ozawa T; Kobayashi M; Tamura Y; Takahashi K; Tanabe M; Tada K; Seto Y; Miyazono K; Koinuma D
Cancer Sci; 2019 Jan; 110(1):209-220. PubMed ID: 30343527
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of human MDA-mB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product.
Elangovan S; Hsieh TC; Wu JM
Anticancer Res; 2008; 28(5A):2641-7. PubMed ID: 19035289
[TBL] [Abstract][Full Text] [Related]
11. The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.
Ono M; Oba T; Shibata T; Ito KI
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3211-3224. PubMed ID: 34244855
[TBL] [Abstract][Full Text] [Related]
12. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
[TBL] [Abstract][Full Text] [Related]
13. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
14. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease.
Sutherland RL; Musgrove EA
Breast Cancer Res; 2009; 11(6):112. PubMed ID: 20067604
[TBL] [Abstract][Full Text] [Related]
15. ER
Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
[No Abstract] [Full Text] [Related]
16. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
Brandi G; Paiardini M; Cervasi B; Fiorucci C; Filippone P; De Marco C; Zaffaroni N; Magnani M
Cancer Res; 2003 Jul; 63(14):4028-36. PubMed ID: 12874002
[TBL] [Abstract][Full Text] [Related]
17. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
[TBL] [Abstract][Full Text] [Related]
18. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
19. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.
Dean JL; McClendon AK; Hickey TE; Butler LM; Tilley WD; Witkiewicz AK; Knudsen ES
Cell Cycle; 2012 Jul; 11(14):2756-61. PubMed ID: 22767154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
